Skip to main content
. 2018 May 22;14(8):971–982. doi: 10.7150/ijbs.23350

Table 3.

Literature verification for the five potential drugs

Drug names Drugbank ID Original indications Supported references for breast cancer
Eribulin mesylate DB08871 anticancer drug 49 50
Nadroparin DB08813 anticoagulan 51
Regorafenib DB08896 oral multi-kinase inhibitor [52][53][54]
Pralatrexate DB06813 anticancer drug 55,56
Tenecteplase DB00031 tissue plasminogen activator [57][58][59]